Logo Scientific Seminars

The 2023 Digital Learning Journey on Hypertension

According to the WHO data, hypertension remains the first cause of death worldwide. In addition, considering the ageing of population, but also the development of countries in emerging area from Asia and Africa, the prevalence of high blood pressure is dramatically increasing. Hypertension Guidelines strongly support blood pressure reduction aimed to reach values lower than 130-80 mmHg by the utilization of the combination therapy. Unfortunately, the most relevant aspect related to a non-effective antihypertensive treatment is the lack of compliance. One of the possibilities to overcome this important limitation is the utilization of single pill combinations. More options are now available, and it is crucial to discuss possible differences in their therapeutic effectiveness. Moreover, a modern therapeutic strategy, in addition to blood pressure reduction, should include a pathophysiological approach targeting to consider all different hypertension-related alterations, including genetic determinants of the disease and its complications or gender differences, important aspects leading to personalized medicine. Finally, since hypertension is often associated to important cardiovascular diseases, it is necessary to tailor treatment according to the specific associated pathological conditions. In addition to classical complications including coronary artery disease or heart failure, it is now important to consider emerging aspects such as cognitive disorders and dementia.


The Virtual Animated Conversations will have Spanish voice over

  • Discuss the most recent evidence addressing the relevant factors limiting the efficacy of therapeutic intervention in patients with cardiovascular disease
  • Identify the rational and clinical advantage to use single pill combinations as first choice therapeutic strategy in hypertensive patients
  • Describe novel evidence concerning the genetic and epigenetic of cardiovascular disease and use this approach for personalized medicine, if the possibility exists
  • Illustrate the pathophysiology of hypertension-related clinical complications, including coronary artery disease or mental disorders and the specific therapeutic approach
  • Identify which the main mechanisms promoting the transition from hypertension to heart failure are

Cardiologists, internal medicine specialists, GPs

  • Virtual Animated Conversations (2 Episodes) on Medication Compliance


  • Episode 1: Poor compliance and cardiovascular risk – Determinants of poor compliance

LAUNCH DATE: 12 April 2023

  • Episode 2: Patients with hypertension suffering from obstructive sleep apnea

LAUNCH DATE: 19 May 2023

  • Online course: Choice of pharmacology for BP control – the importance of the multidisciplinary approach in patients’ management

LAUNCH DATE: 10 July 2023

  • Online course: Hypertension management and emerging hot topics

LAUNCH DATE: 18 December 2023

Share on social

Annamaria Nestico’ | Progamme Manager | annamaria.nestico@scientificseminars.com

This educational program is made possible thanks to an independent educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.

Scientific Seminars Foundation
My Agile Privacy
This website uses technical and profiling cookies. Clicking on "Accept" authorises all profiling cookies. Clicking on "Refuse" or the X will refuse all profiling cookies. By clicking on "Customise" you can select which profiling cookies to activate.
Warning: some page functionalities could not work due to your privacy choices